This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Babies born to pregnant women with obesity are more likely to develop heart problems and diabetes as adults due to fetal damage caused by the high-fat, high-energy diet of their mother.
Obesity is one of the major global health concerns of the 21st century, associated with many comorbidities such as type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease, and early and aggressive atherosclerotic cardiovasculardisease, which is the leading cause of death worldwide.
Background Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovasculardisease. In addition, we investigated the beneficial effects of fenofibrate on HF hospitalization. During the 4.22-year
For over 50 years, rates of those who are overweight or obese have been rising rapidly. Despite the rise in obesity rates, the growing recognition of it as a global problem and the astronomical sums of money we spend on addressing it, the tide continues to rise. That is until now.
Cardiovasculardisease represents a significant risk factor for mortality in individuals with type 2 diabetes mellitus (T2DM). High-density lipoprotein (HDL) is believed to play a crucial role in maintaining c.
This new insight into the flow of fats through the body points to new therapeutic targets for mitigating diseases like ASCVD, non-alcoholic fatty liver disease, obesity, diabetes, peripheral neuropathy, and neurodegeneration.
With Medicare now covering semaglutide for people with obesity and cardiovasculardisease who don't have diabetes, a study looks at who that might include, depending on what cutoffs prescription plans apply.
In the US, over 45% of the population has either diabetes or pre-diabetes 1. The absolute majority of those with diabetes have type 2 diabetes, which is usually associated with excess visceral fat and poor cardiometabolic health. Because a diagnosis of diabetes is very likely to shorten your life. Pre-Diabetes.
In today’s society, the prevalence of obesity has become a significant concern. have obesity, and this rate has increased by more than 10 percentage points in the past two decades. Understanding the prevalence of obesity is crucial in comprehending why events like Healthy Weight Week are essential. of adults in the U.S.
The 2023 Almanac results derived from the Global Burden of Disease (GBD) and spanning 1990 to 2022, were recently published in the Journal of American College of Cardiology. The post Global Trends in CardiovascularDiseases: Insights from the 2023 Almanac appeared first on Cardiology Update. Original article: Mensah GA et al.
Atherosclerosisa key driver of cardiovasculardisease (CVD)continues to be a significant global health issue. The Global Burden of Disease data (2023) highlights a grim reality: while high-income countries have seen some success in managing CVD, LMICs now account for most CVD-related deaths.
“Statins cause diabetes” This one is true. In truth, it is really those who are pre-diabetic who likely pull forward their diagnosis by about five days. But they do not magically take someone who is insulin-sensitive to full-blown type 2 diabetes overnight. 2 JACC: Cardiovascular Imaging May 2015, 8 (5) 579-596;
Obesity is a multifaceted disease that is directly and indirectly implicated in atherosclerotic cardiovasculardisease (CVD), heart failure (HF), atrial fibrillation (AF), and multiple CVD risk factors, including dyslipidemia, hypertension, type 2 diabetes mellitus (DM), and sleep disorders.
Driven by common pathophysiologic underpinnings (eg, inflammation and neurohormonal dysregulation), cardiovasculardisease, cognitive impairment, and frailty also share the following risk factors: hypertension, diabetes, obesity, sedentary behavior, and tobacco use.
A projected rise in heart disease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8 population could be affected by cardiovasculardisease within the next 30 years, according to two new science reports. and Susan F. of the population.
Atherosclerotic cardiovasculardisease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
A new JAMA study revealed that a shocking 90% of US adults are at risk of developing cardiovascular-kidney-metabolic (CKM) syndrome, underscoring the need for preventative action before we face a wave of CKM-related heart disease. Stage 4 (heart disease, with or without kidney disease) – 9.2% in Whites).
years; p < 0.001), had more cardiovascular risk factors, target organ damage and cardiovasculardisease (CVD) in comparison with those without hypertension. These patients were older (65.8 ± 10.9 vs. 51.6 ± 14.7 Conclusions About half of patients attended in primary care settings have hypertension in Spain.
These circadian mechanisms represent potential pathophysiological pathways linking circadian disruption to adverse metabolic health outcomes, including obesity, metabolic syndrome, and type 2 diabetes.
We projected through 2050, overall and by age and race and ethnicity, accounting for changes in disease prevalence and demographics.RESULTS:We estimate that among adults, prevalence of hypertension will increase from 51.2% Diabetes (16.3% to 26.8%) and obesity (43.1% Prevalences of coronary disease (7.8% in 2020 to 61.0%
Research Highlights: In a large, international clinical trial, people with obesity or overweight but not diabetes taking semaglutide for more than 3 years had a 20% lower risk of heart attack, stroke or death due to cardiovasculardisease and lost an.
When it comes to cardiovasculardisease, two of the biggest risk factors we must consider are: ApoB concentration - A measure of the number of circulating lipid particles. Trends in the number of obese and severely obese people by region. Relationship of BMI and Risk Of Diabetes. But only moderately.
For overweight or obese individuals without diabetes, but with pre-existing cardiovasculardisease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows. However, with price reductions or rebates up to 50%, it could meet the benchmark for value in health care.
Cardiovasculardisease (CVD) is the leading cause of death worldwide, accounting for over one-third of all deaths in Singapore. Furthermore, other major risk factors, such as diabetes mellitus, hypertension, elevated low-density lipoprotein levels, and obesity, are steadily rising. billion USD (11.5 billion SGD).
Semaglutide reduces cardiovascular events, regardless of baseline glycated hemoglobin (HbA1c), among people with overweight or obesity and established atherosclerotic cardiovasculardisease, according to a study published online June 22 in Diabetes Care.
Cardiovascular outcomes with exenatide in type 2 diabetes (T2D) according to left ventricular ejection fraction (LVEF): the EXSCEL trial. CI, confidence interval; CVD, cardiovasculardisease; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HHF, hospitalization for heart failure; HR, hazard ratio; NYHA, New York Heart Association.
Pre-eclampsia and heart failure have common risk factors, including hypertension, obesity and diabetes. Multiple logistic regression analysis was used to evaluate the impact of heart failure on the risk of pre-eclampsia, with adjustment for established risk factors and other cardiovasculardiseases.
Introduction Cardiovasculardiseases (CVDs) are the most important cause of premature death and disability worldwide. The etiological risk factors of CVDs are widely known and include dyslipidemia, obesity, diabetes, and chronic cigarette consumption.
In a trial in patients with cardiovasculardisease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8
Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.
2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD). Diabetes Care. 4 Approximately 6.7 NCT06033950.
Obesity has increased in recent years with consequences on diabetes and other comorbidities. Thus, 1 out of 3 diabetic patients suffers cardiovasculardisease (CVD). The network among glucose, immune system, e.
Pregnancy complications such as preeclampsia and gestational diabetes have recently been associated with a higher risk of developing heart disease later in life. But a new study has found obesity before or during pregnancy is the actual root cause of future cardiovasculardisease. “We
Don’t worry—you can still access the 19th Annual CMHC sessions through our On-Demand platform, which offers 14 CME credits across four comprehensive tracks: Cardiorenal Health: Stay up-to-date with the latest on therapies for resistant hypertension, chronic kidney disease markers, and cardiac risk assessment tools.
Cardiovasculardisease (CVD) is the leading cause of pregnancy-related maternal death in the United States, driven by rising rates of hypertension, diabetes mellitus (DM), obesity, smoking, and advanced maternal age.
Ballantyne, MD , emphasized that while fellows may consider prevention “boring,” it is crucial for avoiding resource-intensive late-stage cardiovasculardisease (CVD). He highlighted that cardiovascular health is essential for cognitive health, noting the common occurrence of vascular dementia.
It all comes down to: What your priorities are What your objectives are Your risk tolerance Your ability to update that risk model Where you draw the line of ‘risk’ equating to ‘causation’ The same is true when it comes to the question of statins ‘causing’ diabetes. What to do? Let’s dive in.
Less than two weeks after Novo Nordisk’s weight-loss drug Wegovy gained expanded FDA approval for cardiovascular event risk reduction, CMS issued a new Medicare Part D guidance that allows coverage of obesity drugs for senior patients with “an additional medically accepted indication”… like cardiovasculardisease.
Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovasculardisease, and chronic kidney disease. The robust conference agenda begins with FDA updates and advancements in cardiorenal metabolic care.
What is the value of the new American Heart Association’s (AHA’s) PREVENT equation(s) for primary prevention that use routinely available clinical variables including obesity, diabetes, kidney disease, and social risk for predicting 10- and 30-year absolute risk of cardiovasculardisease (CVD) including each atherosclerotic CVD (ASCVD) and heart (..)
While moderate alcohol consumption may improve insulin response in some individuals, excessive drinking can lead to insulin resistance, increasing the risk of diabetes and contributing to cardiovasculardisease.
Aims:Asian Americans experience disproportionate burdens of cardiovascular risk factors and cardiovasculardisease (CVD). However, the trends in cardiovascular risks in adults from different Asian ethnic backgrounds remain understudied. Asian Indian adults exhibited uptrends in overweight/obesity (AAPC: 1.1%,p<
Similar patterns have been observed for cardiovasculardisease and also cancer. Less major diseases earlier in life. Therefore, even if living longer is not a priority, delaying the onset of a major chronic disease should be. More steps are linked to: Less obesity. Less gastroesophageal reflux disease.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content